Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression
2011 (English)In: Journal of Neuroimmunology, ISSN 0165-5728, E-ISSN 1872-8421, Vol. 233, no 1-2, 221-227 p.Article in journal (Refereed) Published
The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. All of these values subsided in 10-year sufferers. Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets.
Place, publisher, year, edition, pages
2011. Vol. 233, no 1-2, 221-227 p.
Parkinson's disease; α-synuclein; amyloid toxicity; autoantibodies; T-cells; B-cells
IdentifiersURN: urn:nbn:se:umu:diva-42957DOI: 10.1016/j.jneuroim.2010.12.001PubMedID: 21239064OAI: oai:DiVA.org:umu-42957DiVA: diva2:410826